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        Introduction 
  The TRIM5 family of proteins has recently been identifi  ed as a 
class of restriction factors that can act as a barrier to the cross-
species transmission of retroviruses, which is exemplifi  ed by 
the ability of TRIM5     from rhesus macaques (rhesus macaque 
TRIM5     [rhTRIM5   ]) to restrict HIV-1 infection (  Stremlau 
et al., 2004  ). TRIM5    -mediated restriction of retroviral infection 
involves the specifi  c recognition of determinants present on the 
capsid of the targeted retrovirus (  Bieniasz, 2004  ;   Goff, 2004  ; 
  Stremlau et al., 2004  ). These determinants in retroviral capsids are 
recognized by the C-terminal B30.2 domain of TRIM5 proteins, 
and the amino acids that dictate antiviral specifi  city have been 
identifi  ed (  Stremlau et al., 2005  ;   Yap et al., 2005  ). Moreover, in 
vitro studies demonstrate that TRIM5 proteins associate with 
viral capsid structures (  Sebastian and Luban, 2005  ;   Stremlau 
et al., 2006  ). Importantly, these studies show that TRIM5     does 
not recognize or bind free capsid protein but rather binds capsid 
protein in the context of an intact, mature viral core (  Sebastian 
and Luban, 2005  ;   Stremlau et al., 2006  ). 
  Although the regions within the B30.2 domain that con-
tribute to retroviral capsid binding have been mapped, less is 
known about the mechanism by which TRIM5 proteins restrict 
retroviral infection after capsid recognition. It is known that 
  virions encounter this replicative block before the accumulation 
of viral reverse transcription (RT) products (  Towers et al., 2000; 
Cowan et al., 2002  ;   Stremlau et al., 2004  ). 
  Our laboratory has recently found that proteasome in-
hibition abrogates the ability of TRIM5 proteins to prevent the 
  accumulation of RT products but does not relieve the ability of 
TRIM5 proteins to restrict viral infection (  Anderson et al., 2006  ; 
  Wu et al., 2006  ). In the presence of proteasome inhibitor, viri-
ons complete RT and form functional preintegration complexes 
(PICs), but infection and 2  –  long terminal repeat circle forma-
tion remains impaired (  Anderson et al., 2006  ;   Wu et al., 2006  ). 
As 2  –  long terminal repeat circles can act as surrogate markers 
of the nuclear entry of retroviral cDNA, this suggests that in-
coming viral PICs are unable to access the nucleus under these 
conditions, although the mechanism by which nuclear access is 
inhibited is currently unknown. 
  TRIM5 proteins belong to a larger family of TRIM pro-
teins that were originally observed to oligomerize into high-order 
structures localizing to specifi  c cellular compartments in the 
cytoplasm and nucleus (  Reymond et al., 2001  ). rhTRIM5     and  its 
T
RIM5 proteins constitute a class of restriction factors 
that prevent host cell infection by retroviruses from 
different species. TRIM5     restricts retroviral infec-
tion early after viral entry, before the generation of viral 
reverse transcription products. However, the underlying 
restriction mechanism remains unclear. In this study, we 
show that during rhesus macaque TRIM5     (rhTRIM5    )  –
  mediated restriction of HIV-1 infection, cytoplasmic HIV-1 
viral complexes can associate with concentrations of 
TRIM5     protein termed cytoplasmic bodies. We observe a 
dynamic interaction between rhTRIM5     and cytoplasmic 
HIV-1 viral complexes, including the de novo formation of 
rhTRIM5     cytoplasmic body  –  like structures around viral 
complexes. We observe that proteasome inhibition allows 
HIV-1 to remain stably sequestered into large rhTRIM5     
cytoplasmic bodies, preventing the clearance of HIV-1 
viral complexes from the cytoplasm and revealing an inter-
mediate in the restriction process. Furthermore, we can 
measure no loss of capsid protein from viral complexes 
arrested at this intermediate step in restriction, suggesting 
that any rhTRIM5    -mediated loss of capsid protein re-
quires proteasome activity.
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during proteasome inhibition (  Fig. 1 A  ) was specifi  c to viral 
complexes that had fused and entered the cytoplasm. 
 First,  rhTRIM5    cells were incubated for 6 h in MG132 
with HIV-1 lacking a functional envelope protein (  Env) to block 
fusion or were pseudotyped with vesicular stomatitis virus G 
(VSV-G) envelope protein to allow the productive entry of virions 
into target cells. HIV-1 localization with rhTRIM5     bodies was 
compared (  Fig. 1 B   and   Table I  ). In data compiled from two inde-
pendent experiments, 35.1% of 698 VSV-G  –  pseudotyped virions 
localized to rhTRIM5     cytoplasmic bodies. Conversely, only 
2.5% of 837 viral complexes lacking envelope protein associated 
with rhTRIM5     under similar conditions, indicating that it is the 
fused viral complexes that have entered the cytoplasm and are 
susceptible to restriction that interact with rhTRIM5     cytoplas-
mic bodies formed in the presence of the proteasome inhibitor. 
  We also examined whether this association occurred when 
viral entry into target cells was mediated by the HIV-1 enve-
lope protein. To allow for entry of these wild-type HIV-1 viri-
ons into rhTRIM5    -expressing HeLa cells, the cells were 
transfected with a CFP-CD4 fusion protein that has been pre-
viously shown to be functional in mediating HIV-1 envelope  –
    mediated fusion (  Steffens and Hope, 2003  ). These transfected 
cells were then spinoculated (  O  ’  Doherty et al., 2000  ) at 17  °  C 
with GFP-Vpr  –  labeled wild-type NL43 virus in the presence 
of MG132. The CXCR4-specifi  c fusion inhibitor AMD3100 
was included as a control in these experiments. When the degree 
of TRIM5    association of these viral complexes was determined, 
12.4% of 418 viral complexes were observed to associate with 
TRIM5     signal 6 h after infection (  Fig. 1 C   and   Table I  ), 
whereas only 7.3% of 369 viral complexes were observed to as-
sociate with TRIM5     signal when the infection was performed 
in the presence of AMD3100. This difference in the degree of 
association observed between viral complexes pseudotyped with 
the VSV-G envelope protein and those possessing native HIV-1 
envelope is likely because VSV-G mediates the cytoplasmic 
entry of viral complexes much more effi  ciently than HIV-1 
envelope (  Luo et al., 1998  ). However, given the relatively 
smaller degree of association observed in this system, and as re-
striction by TRIM5     is known to occur independently of the 
envelope protein used (  Hofmann et al., 1999  ;   Stremlau et al., 
2004  ), we used virions pseudotyped with the VSV-G envelope 
protein in all subsequent experiments. 
  To gain further insight into the association of HIV-1 and 
rhTRIM5    , we also examined this interaction using HIV-1 viri-
ons dually labeled with GFP-Vpr and S15-mCherry to identify 
virions that had productively entered the target cell. We have re-
cently demonstrated that this S15-mCherry protein is effi  ciently 
incorporated into HIV-1 virions (  Campbell et al., 2007b  ). As this 
fl  uorescent membrane label is lost from the virion core after 
fusion, this system can effectively discriminate between virions 
that remain intact and unfused (S15 
+   and  Vpr 
+  ) from those that 
have fused and productively entered the cell cytoplasm (S15 
     
and Vpr 
+ ).  rhTRIM5   -expressing cells were incubated with 
these dually labeled virions in the presence of MG132 for 6 h, 
and virion association with rhTRIM5     bodies was assessed. As a 
control, the experiment was also performed with bafi  lomycin A 
(BafA), which blocks endosomal acidifi  cation by inhibiting 
primate counterparts are known to form discreet concentrations 
in the cytoplasm referred to as cytoplasmic bodies (  Stremlau et al., 
2004  ). A second population of TRIM5     exists with a diffuse 
cytoplasmic localization. Formation of the cytoplasmic bodies 
is concentration dependent. We have recently reported that 
TRIM5     is continuously exchanging between the cytoplasmic 
pool and the subset of rhTRIM5     protein present in cytoplas-
mic bodies (  Campbell et al., 2007a  ). The potential importance 
of TRIM5     cytoplasmic bodies remains controversial, primar-
ily because there are no antibodies available that can determine 
whether these structures are formed by endogenous expression 
levels of the protein. Preliminary examination of the role of these 
bodies in restriction showed that preexisting cytoplasmic bodies 
were not required for retroviral restriction by TRIM5 proteins 
(  Perez-Caballero et al., 2005b  ;   Song et al., 2005  ). Importantly, 
however, these studies only examined the requirement for pre-
existing cytoplasmic bodies in restriction and did not examine 
TRIM5 localization after virus addition. For clarity, we defi  ne a 
cytoplasmic body as being a discrete, observable accumulation 
of rhTRIM5     signal above background. 
  In this study, we use fl  uorescently labeled HIV-1 particles 
to examine the fate of these viral complexes during restriction. 
We fi nd that HIV-1 viral complexes associate with rhTRIM5    
cytoplasmic bodies in live and fi  xed cell experiments. We also 
fi  nd that proteasome inhibition prevents the clearance of HIV-1 
viral complexes from the cytoplasm and leads to the stable se-
questration of these complexes in cytoplasmic bodies, where they 
still contain readily detectable amounts of p24. Collectively, these 
results suggest a model in which the association of discreet con-
centrations of rhTRIM5     (currently known as cytoplasmic bod-
ies) with cytoplasmic HIV-1 viral complexes is a key intermediate 
in the restriction process leading to the proteasome-dependent 
destruction of these viral complexes. 
  Results 
  HIV-1 viral complexes accumulate in 
rhTRIM5     cytoplasmic bodies after 
proteasome inhibition 
 We  fi rst examined the fate of HIV-1 particles in restricted cells 
after proteasome inhibition. To this end, HeLa cells stably ex-
pressing HA-tagged rhTRIM5    , which have been shown to po-
tently restrict HIV-1 infection (  Stremlau et al., 2004  ), were 
incubated with GFP-Vpr  –  labeled HIV-1 virions (  McDonald et al., 
2002  ) in the presence of the proteasome inhibitor MG132 for 
6 h, and the localization of TRIM5     and HIV-1 viral complexes 
was examined. As we previously reported, rhTRIM5     localized 
into large cytoplasmic bodies after 6 h of MG132 treatment 
(  Fig. 1 A    ; Wu et al., 2006  ). HIV-1 viral complexes clearly local-
ized to these cytoplasmic bodies, and accumulations of viral com-
plexes were often observed in these large cytoplasmic bodies 
(  Fig. 1 A  , insets), where they appear to be sequestered. 
  TRIM5 proteins restrict retroviruses by interacting with 
incoming retroviral cores that are released into the cell cytoplasm 
after fusion of the virion and cell membranes (  Bieniasz, 2004  ; 
  Goff, 2004  ). Therefore, we investigated whether the association 
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fused virus that did not appreciably associate with rhTRIM5    
(  Fig. 1 D  , black bars; and   Table I  ). In data compiled from three 
independent experiments examining a total of 1,445 viral com-
plexes, 93.1% of viral complexes were S15 
+   (unfused) and not 
the vacuolar ATPase and thus blocks the pH-dependent fusion 
of  VSV-G – pseudotyped  virions. 
  In the control experiment with the BafA fusion inhibitor, 
the viral population was almost exclusively dually labeled un-
  Figure 1.       Proteasome inhibition induces the accumulation of HIV-1 in rhTRIM5     cytoplasmic bodies.   (A) rhTRIM5    -HA  –  expressing HeLa cells were con-
tinuously infected with GFP-Vpr  –  labeled HIV-1 virions (green) in the presence of 1     g/ml MG132 proteasome inhibitor for 6 h. Cells were then ﬁ  xed and 
immunostained with antibodies to HA (red) or the 20s proteasomal subunit (blue) and imaged. The boxed regions are enlarged in the insets to the right 
for better visualization of the described interaction. The provided image is one z section from a deconvolved z-stack image. (B) The percentage of HIV-1 
virions associated with rhTRIM5     cytoplasmic bodies was calculated for virions lacking envelope protein (    Env) or pseudotyped with the VSV-G enve-
lope protein (VSV-G). The mean of two independent experiments is shown in which a total of 698 virions (VSV-G) and 837 virions (    Env) were counted. 
(C) rhTRIM5    -HA  –  expressing HeLa cells were spinoculated with GFP-Vpr  –  labeled NL43 virions in the presence of 1     g/ml MG132, and the percentage of 
HIV-1 virions associated with rhTRIM5     cytoplasmic bodies was calculated for virions infected in the presence of absence of AMD3100. The mean of two 
independent experiments is shown in which a total of 369 virions (MG132) and 418 virions (MG132 + AMD3100) were counted. (D) The ability of fused 
and unfused HIV-1 virions to associate with rhTRIM5     cytoplasmic bodies was analyzed using HIV-1 dually labeled with S15-mCherry and GFP-Vpr. Cells 
were infected in the presence of 1     g/ml MG132 (gray bars) or 20 nM BafA (black bars). Error bars represent the SEM from three experiments in which 
a total of 2,578 or 1,445 virions were counted for cells treated with MG132 or BafA, respectively.     JCB • VOLUME 180 • NUMBER 3 • 2008  552 
ation was only detectable at earlier times after infection as op-
posed to the case of proteasome inhibition, which induces the stable 
accumulation of viral complexes within enlarged rhTRIM5    
cytoplasmic bodies. Moreover, although the association be-
tween HIV-1 and rhTRIM5     was readily observed in the pres-
ence of proteasome inhibitor, this interaction in the absence of 
drug was not frequently observable. This is consistent with the 
notion that in the absence of drug, restriction occurs rapidly af-
ter the entry of viral complexes into the target cell as previously 
reported (  Perez-Caballero et al., 2005b  ). 
  HIV-1 viral complex association with rhTRIM5     bodies 
requires the rhTRIM5     B30.2 domain that recognizes HIV-1 
capsid and is essential for HIV-1 restriction. Recent studies show 
that elements in the C-terminal B30.2 domain of TRIM5 proteins 
mediate their ability to recognize specifi  c retroviral capsids ( Sawyer 
et al., 2005  ;   Stremlau et al., 2005  ;   Yap et al., 2005  ). Moreover, re-
moval of a positively selected 13  –  amino acid patch of this do-
main (    patch) abrogates the ability of rhTRIM5     to restrict HIV-1 
infection (  Sawyer et al., 2005  ). Therefore, we next tested whether 
this region in the rhTRIM5     B30.2 domain, which is critical for 
recognizing retroviral capsid and restricting HIV-1, was also re-
quired for HIV-1 association with rhTRIM5     cytoplasmic bodies. 
  To this end, we used CRFK feline cells stably expressing 
HA-tagged versions of either wild-type rhTRIM5   or rhTRIM5   
containing the     patch mutations in the B30.2 domain (  Sawyer 
et al., 2005  ). Microscopic examination of both cell lines re-
vealed that both the wild-type and    patch  rhTRIM5    formed 
cytoplasmic bodies (  Fig. 3 A  ). These cells were then infected 
with S15-mCherry and GFP-Vpr dually labeled HIV-1 virions, 
and association of these viral complexes with the wild-type 
or    patch  rhTRIM5    bodies was examined. For these experi-
ments, cells were synchronously infected as previously described 
(  Campbell et al., 2007b  ). Cells were infected without drug and 
fi  xed 90 min after the infection was initiated by raising the tem-
perature to 37  °  C (  Fig. 3 B  ). For the cells expressing wild-type 
rhTRIM5    , 32.2% of 432 fused (S15 
     ) viral complexes associated 
with rhTRIM5     bodies over three independent experiments. 
associated with rhTRIM5     in the presence of BafA. We also 
observed 5.1% of viral complexes that were S15 
      and not asso-
ciated with rhTRIM5     bodies (  Fig. 1 D   and   Table I  ), although 
these viral complexes likely represent virions ineffi  ciently la-
beled with the S15-mCherry protein (  Campbell et al., 2007b  ). 
Importantly, only 1.7% of these viral complexes (S15 
+   and  S15 
    ) 
associated with rhTRIM5     bodies (  Fig. 1 D   and   Table I  ) in the 
presence of this fusion inhibitor. 
  In the MG132-treated cells, a greater percentage of HIV-1 
associated with rhTRIM5     signal compared with the BafA con-
trol ( Fig. 1 C  and  Table I ). Moreover, the population of HIV-1 that 
associated with rhTRIM5     signal during MG132 treatment had 
fused and lost their membrane (S15 
     ). In 2,578 viral complexes 
counted from four independent experiments, 26.6% of viral com-
plexes were S15 
      (fused) and associated with rhTRIM5     bodies 
compared with only 2.0% of S15 
+   (unfused) viral complexes as-
sociated with rhTRIM5     bodies (  Fig. 1 C   and   Table I  ). There-
fore, these data collectively reveal that incoming HIV-1 viral 
complexes that have fused and entered the cell cytoplasm can as-
sociate with rhTRIM5     cytoplasmic bodies in cells treated with 
proteasome inhibitors. Sequestration within these bodies pro-
vides a plausible mechanistic explanation for our previous obser-
vation that proteasome inhibitors allow RT and PIC formation by 
restricted viral complexes but that these complexes are unable to 
enter the nucleus (  Anderson et al., 2006  ;   Wu et al., 2006  ). 
  HIV-1 viral complexes associate with 
rhTRIM5     bodies in the absence of drug 
  As HIV-1 interacted with rhTRIM5     cytoplasmic bodies during 
proteasome inhibition, we examined whether HIV-1 also inter-
acted with rhTRIM5     bodies in the absence of drug. When 
rhTRIM5    -expressing cells were continuously infected with 
GFP-Vpr  –  labeled virions for 2 h in the absence of drug, it was 
possible to observe HIV-1 viral complexes associating with 
rhTRIM5     signal, although rhTRIM5     accumulated in smaller 
cytoplasmic bodies (  Fig. 2  ) compared with the relatively larger 
bodies observed after MG132 treatment (  Fig. 1 A  ). This associ-
  Table I.       Comparative analysis of HIV-1 association with rhTRIM5       
Viral  
  envelope
Cell type Treatment Total TRIM  
  association 
TRIM association
S15 
+    
  (unfused)
S15 
       
  (fused)
  %   %   % 
VSV-G rhTRIM-HA HeLa MG132 35.1 (Fig. 1 B) ND ND
None rhTRIM-HA HeLa MG132 2.5 (Fig. 1 B) ND ND
HIV rhTRIM-HA HeLa MG132 12.4 (Fig. 1 C) ND ND
HIV rhTRIM-HA HeLa MG132 + AMD3100 7.3 (Fig. 1 C) ND ND
VSV-G rhTRIM-HA HeLa BafA 1.7   
a    1.5 (Fig. 1 D) 5.1 (Fig. 1 D)
VSV-G rhTRIM-HA HeLa MG132 28.6   
a    5.0 (Fig. 1 D) 44.7 (Fig. 1 D)
VSV-G rhTRIM-HA CRFK No drug 17.8   
a    4.7 (Fig. 3 B) 32.1 (Fig. 3 B)
VSV-G rh  Δ  patch-HA CRFK No drug 5.1   
a    3.2 (Fig. 3 B) 7.5 (Fig. 3 B)
VSV-G rhTRIM-HA CRFK MG132 13.7   
a    5.4 (Fig. 3 C) 26.5 (Fig. 3 C)
VSV-G rh  Δ  patch-HA CRFK MG132 6.9   
a    6.2 (Fig. 3 C) 7.9 (Fig. 3 C)
Data from the experiments averaged in   Figs. 1 and 3   were pooled to examine the percentage of all viral particles associating with rhTRIM5     under all conditions 
examined. The ﬁ  gure from which the pooled data were derived is indicated in parentheses.
 
a  In the case of experiments examining S15-mCherry, data were pooled to determine the degree of rhTRIM5     associations in both S15 
+   and S15 
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Therefore, both with and without MG132, rhTRIM5     requires 
the patch region in its B30.2 domain for rhTRIM5     cytoplas-
mic bodies to effi  ciently interact with fused HIV-1 viral com-
plexes (  Fig. 3, B and C  ) as well as mediate restriction (  Sawyer 
et al., 2005  ). This indicates that rhTRIM5     recognition and re-
striction of HIV-1 viral complexes correlates with and involves 
HIV-1 interaction with rhTRIM5     cytoplasmic bodies. 
  Proteasome inhibition causes rhTRIM5    -
speciﬁ  c accumulation of cytoplasmic HIV-1 
viral complexes in target cells 
  To examine viral populations under conditions of restriction 
and proteasome inhibition, we performed a synchronized infec-
tion with S15-mCherry  –   and GFP-Vpr  –  labeled HIV-1 virions 
and compared the viral populations present in HeLa cells stably 
expressing rhTRIM5     or control HeLa cells at 1 or 4 h after in-
fection, both in the presence or absence of MG132. The number 
of S15 
      (fused) and S15 
+   (unfused) viral complexes per cell 
was counted for each sample. To normalize for differences in 
viral input between experiments, these values were expressed as 
percentages of the total number of viral complexes per cell 
counted in the control sample containing BafA, which blocks 
In contrast, only 4.7% of 473 unfused (S15 
+  ) viral complexes 
associated with rhTRIM5     cytoplasmic bodies, again demon-
strating that HIV-1 interacts with rhTRIM5     bodies after fusion 
and entry into the cytoplasm (  Fig. 3 B   and   Table I  ). Conversely, 
for the cells expressing rhTRIM5      patch, only 7.1% of 379 
fused (S15 
     ) viral complexes associated with cytoplasmic bod-
ies. This degree of association likely represents the background 
degree of association in these experiments, as a similar degree 
of association was observed for unfused viral complexes (S15 
+ ) 
in both cell lines. 
  Similar experiments were performed in the presence of 
MG132 using cells analyzed 4 h after synchronized infection 
(  Fig. 3 C   and   Table I  ). For the cells expressing wild-type 
rhTRIM5    , 26.4% of 654 fused (S15 
     ) viral complexes asso-
ciated with rhTRIM5     bodies, whereas only 5.4% of 1,014 
 unfused  (S15 
+  ) viral complexes associated with rhTRIM5     bod-
ies (  Fig. 3 C   and   Table I  ). Moreover, for the cells expressing 
rhTRIM5      patch, only 7.9% of 693 fused (S15 
     ) viral com-
plexes and 6.2% of 1,020 unfused (S15 
+  ) viral complexes asso-
ciated with the rhTRIM5    patch bodies with MG132 treatment 
(  Fig. 3 C   and   Table I  ). Again, this level likely represents the 
background amount of association observed in these experiments. 
  Figure 2.       HIV-1 interacts with rhTRIM5     cytoplasmic bodies in the absence of drug.   (A) rhTRIM5    -HA  –  expressing HeLa cells were continuously infected 
with GFP-Vpr  –  labeled HIV-1 virions (green) for 2 h. Cells were ﬁ  xed and immunostained with anti-HA antibody (red) or Hoechst to visualize cellular DNA 
(blue). Arrows indicate HIV-1 virions associated with rhTRIM5     cytoplasmic bodies. The boxed area in the top left panel has been enlarged in the other 
three panels, and the ﬂ  uorescent signals for either rhTRIM5    , GFP-Vpr HIV-1, or both (merge) are shown for clarity. The provided image is one z section 
from a deconvolved z-stack image.     JCB • VOLUME 180 • NUMBER 3 • 2008  554 
This trend is apparent at 1 h after infection and becomes more 
pronounced at 4 h after infection. At 4 h after infection, this dif-
ference is statistically signifi  cant (P = 0.0152). This indicates 
that MG132 is specifi  cally increasing the number of fused viral 
complexes in the rhTRIM5    -expressing cells compared with 
the HeLa cells by 4 h after infection. This observation correlates 
well with our previous report that MG132 treatment allows the 
accumulation of HIV-1 RT products and formation of functional 
PICs but does not abrogate the ability of rhTRIM5     to  restrict 
infection (  Anderson et al., 2006  ;   Wu et al., 2006  ). Here, the in-
creased number of fused cytoplasmic HIV-1 viral complexes 
observed in the presence of MG132 indicates that rhTRIM5    
can effectively interrupt the normal traffi  cking of viral complexes 
under these conditions. 
  rhTRIM5     cytoplasmic bodies containing 
HIV-1 viral complexes after proteasome 
inhibition stain positively for ubiquitin 
  As proteasome-mediated degradation requires ubiquitination, we 
examined whether the rhTRIM5     bodies containing sequestered 
VSV-G  –  mediated fusion and viral degradation mediated by 
 endosomal  acidifi  cation (  Fig. 4 A  ). 
  At 1 and 4 h after infection, similar numbers of fused viral 
complexes were observed in the control HeLa and rhTRIM5   -
expressing HeLa cells in the absence of MG132 ( Fig. 4, A and B ), 
suggesting that virions productively enter both cell types at 
similar rates. MG132 treatment increased the number of un-
fused virions present in both cell types 1 and 4 h after infection. 
This is likely caused by the fact that monoubiquitination regu-
lates traffi  cking within the endosomal/lysosomal pathway (for 
review see   d  ’  Azzo et al., 2005  ). Therefore, depletion of the 
ubiquitin pool by proteasome inhibitors alters vesicular traffi  ck-
ing. This would change the rate at which these pseudotyped virions 
are able to productively enter cells using the VSV-G envelope 
protein and subsequently increase the amount of virus within 
the endosomal compartment. 
  Importantly, in addition to this global effect of delayed entry 
kinetics, we also observed a specifi  c increase in the number of 
fused viral complexes present in rhTRIM5    -expressing cells rel-
ative to HeLa control cells in the presence of MG132 (  Fig. 4 B  ). 
  Figure 3.       HIV-1 association with rhTRIM5     cytoplasmic bodies requires the rhTRIM5     B30.2 domain essential for recognizing HIV-1 capsids and restriction. 
  (A) CRFK cells stably expressing HA-tagged wild-type (wt) rhTRIM5     or rhTRIM5        patch were immunostained with anti-HA antibody, and protein localiza-
tion was visualized microscopically. The provided image is one z section from a deconvolved z-stack image. (B and C) Each cell line was also infected with 
VSV-G  –  pseudotyped HIV-1 virions dually labeled with S15-mCherry and GFP-Vpr in a synchronized infection. Cells were ﬁ  xed either 90 min after infection 
(B) or 4 h after infection in the presence of MG132 (C), immunostained with anti-HA antibody, and imaged. The association of both unfused (S15 
+  ) and 
fused (S15 
     ) HIV-1 virions with the HA-positive cytoplasmic bodies was examined in both cell lines. The mean results from three independent experiments 
are graphed, counting a total of 1,716 (B) and 3,381 virions (C). Error bars represent the SEM from three experiments.     555  ASSOCIATION OF HIV-1 WITH RHESUS TRIM5       •   CAMPBELL ET AL.
HIV-1 viral complexes also contained ubiquitin. In the presence 
of MG132, the cytoplasmic bodies stained positively for ubiqui-
tin (  Fig. 4 C  ). Ubiquitin localized to entire cytoplasmic body 
structures, similar to a previous study ( Diaz-Griffero et al., 2006 ), 
but did not intensify on or around viral complexes (  Fig. 4 C  ). 
This demonstrates that rhTRIM5     cytoplasmic bodies contain-
ing HIV-1 viral complexes also contain ubiquitin and further 
suggests that these complexes could be degraded in a protea-
some-mediated manner in the absence of MG132. 
  The viral intermediate associated with 
cytoplasmic bodies after proteasome 
inhibition contains abundant capsid protein 
  HIV-1 capsid protein (p24 
CA  ) forms the conical capsid structure 
containing the viral genome in mature virions. Interaction of 
rhTRIM5     with HIV-1 is mediated through interaction with 
this structure (  Stremlau et al., 2006  ). This conical capsid is re-
leased into the cytoplasm after fusion between virion and target 
cell membranes. It has recently been suggested by other groups 
that TRIM5     restriction may occur via a mechanism that in-
volves either the targeted degradation of p24 
CA   from viral cores 
(  Chatterji et al., 2006  ) or the accelerated loss of p24 
CA   from  the 
viral core during uncoating (  Stremlau et al., 2006  ). Previously, we 
have been able to identify the association of p24 
CA   with RT com-
plexes using a p24 
CA -specifi  c monoclonal antibody (  McDonald 
et al., 2002  ). However, because of the protein-dense nature of 
the cytoplasmic bodies induced after proteasome inhibition, we 
were concerned that antibodies may have a limited ability to 
penetrate these structures during immunostaining, potentially 
confounding our analysis. Therefore, to investigate the effect of 
rhTRIM5     on  p24 
CA   association with cytoplasmic HIV-1 viral 
complexes, we developed an HIV-1 strain containing a tetra-
cysteine tag within the capsid protein (HIV  FC  ). This tag can be 
effectively labeled with the fl  uorescent FlAsH reagent (  Adams 
et al., 2002  ). By combining this technology with our ability to 
fl  uorescently label virions with mCherry-Vpr, we sought to de-
termine the presence or absence of capsid protein on HIV-1 viral 
complexes sequestered within rhTRIM5     cytoplasmic bodies in 
the presence of proteasome inhibitor. 
  Initial characterization of this HIV  FC   virus indicated that 
insertion of the tag into the capsid protein severely impaired 
the ability of the virus to infect unrestricted HeLa target cells 
(Fig. S1 A, available at http://www.jcb.org/cgi/content/full/
jcb.200706154/DC1). However, using an approach described 
by others previously (  Muller et al., 2004  ), we found that viri-
ons produced by transfecting an equal amount of wild-type 
HIV-1 and modifi  ed HIV  FC   plasmids generated mixed particles 
(HIV  FCM  ) that could now effi  ciently infect unrestricted HeLa 
  Figure 4.       Proteasome function is required for rhTRIM5    -mediated loss 
of HIV-1 virions.   HeLa cells or rhTRIM5    -HA  –  expressing HeLa cells were 
synchronously infected with S15-mCherry  –   and GFP-Vpr  –  labeled virions in 
the presence of 1     g/ml MG132 or 20 nM BafA or in the absence of drug 
as indicated. (A and B) Cells were ﬁ  xed for 1 (A) or 4 h (B) after the initia-
tion of infection, and the number of fused (S15 
+  ; black bars) and unfused 
(S15 
     ; gray bars) virions per cell was calculated. All values are expressed 
as a percentage of the total virions per cell (fused and unfused) present in 
the BafA sample at 1 h. The mean results from three independent experi-
ments examining a total of 493 cells and 11,727 virions are graphed. 
Error bars represent the SEM from three independent experiments. 
The difference in values indicated by the asterisk are statistically signiﬁ  cant 
(*, P = 0.0152). (C) HeLa cells stably expressing rhTRIM5     were continu-
ously infected with GFP-Vpr  –  labeled HIV-1 virions (green) in the presence 
of 1     g/ml MG132 for 6 h. Cells were then ﬁ  xed and immunostained with 
anti-HA antibody (red) and antiubiquitin antibody (blue). The provided im-
age is one z section from a deconvolved z-stack image.     
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examine whether HIV-1 viral complexes sequestered in rhTRIM5   
cytoplasmic bodies contained or lacked p24 
CA . 
  To determine whether HIV-1 viral complexes sequestered 
in rhTRIM5     cytoplasmic bodies contained or lacked p24 
CA , 
target cells (Fig. S1 A) as well as be effectively labeled by the 
FlAsH reagent (Fig. S1 B). This virus was also still completely 
restricted when used to infect HeLa cells stably expressing 
rhTRIM5    -HA (Fig. S1 A). Therefore, we used this virus to 
  Figure 5.       HIV-1 virions sequestered within rhTRIM5     cytoplasmic bodies after proteasome inhibition contain p24 
CA   protein.   (A and B) HeLa cells stably 
expressing HA-tagged rhTRIM5     were spinoculated with VSV-G  –  pseudotyped HIV  FCM   containing FlAsH-labeled capsid and mCherry-Vpr for 2 h at 17  °  C. 
Unbound virus was removed and replaced with media, and cells were incubated for 6 h at 37  °  C in the presence of MG132. Cells were then ﬁ  xed, stained 
with an HA-speciﬁ  c antibody, and analyzed by ﬂ  uorescent microscopy to determine the total number of mCherry-Vpr 
+   virions/cell and the percentage of 
virions that associated with rhTRIM5     signal (B). (C) The ﬂ  uorescent FlAsH intensity of mCherry-Vpr virions associated with rhTRIM5     signal in the MG132-
treated sample was compared with the intensity of virions observed in the untreated and BafA infections. The mean FlAsH intensity of each population is 
indicated by black bars. (D) HIV  FCM   particles positive for both FlAsH-labeled capsid (green) and mCherry-Vpr (red) within rhTRIM5     cytoplasmic bodies 
(blue). The provided image is one z section from a deconvolved z-stack image.     557  ASSOCIATION OF HIV-1 WITH RHESUS TRIM5       •   CAMPBELL ET AL.
complex was derived from protein originally present in the fi  rst 
preexisting body. 
  In the third type of interaction, we observed the de novo 
forma tion of YFP-rhTRIM5     cytoplasmic bodies on or around 
mCherry-Vpr  –  labeled viral complexes (  Fig. 7 C   and Videos 4 
and 5, available at http://www.jcb.org/cgi/content/full/jcb
.200706154/DC1). Quantifying this interaction revealed that body 
formation in this type of interaction is very rapid, with body 
  intensity reaching its maximal intensity in   <  1 min (  Fig. 7 D   
and Fig. S2 B). Unfortunately, it was not possible to reliably 
quantify the fate of these YFP-rhTRIM5     body – associated  vi-
ral complexes, as the outcomes of most interactions could not 
be ascertained before the end of the acquisition time. However, 
during the short period of analysis, we did observe two different 
outcomes in the cases in which the interaction appeared to ter-
minate. In some cases (Videos 4 and 5), the fl  uorescent signal of 
mCherry-Vpr  –  labeled HIV-1 viral complexes disappeared dur-
ing the acquisition time. Alternatively, in other examples, the 
YFP-rhTRIM5      –  associated viral complexes separated from the 
cytoplasmic body without detectable YFP-rhTRIM5     remain-
ing with the virus (Video 3). Therefore, these time-lapse images 
suggest that the dynamic nature of rhTRIM5     cytoplasmic  bod-
ies allows this protein to rapidly recognize and respond to cyto-
plasmic HIV-1 viral complexes during restriction. 
  Discussion 
  A proteasome-sensitive intermediate 
of restriction 
  In this study, we demonstrate that rhTRIM5   -mediated  restric-
tion in the presence of proteasome inhibitors induces the accumu-
lation of HIV-1 viral complexes within rhTRIM5     cytoplasmic 
concentrations termed cytoplasmic bodies ( Stremlau et al., 2004 ), 
where they are apparently sequestered (  Fig. 1 A  ). In the presence 
of proteasome inhibitors, we could measure a statistically signifi  -
cant retention of HIV-1 viral complexes in the cytoplasm of re-
stricted cells relative to control cells (  Fig. 4 B  ). The fi  nding that 
proteasome inhibitors induce the stable accumulation of viral 
complexes in cytoplasmic bodies also indicates that proteasome 
inhibition allows an intermediate step in the restriction process to 
be observed. Our previous work has demonstrated that protea-
some inhibition allows HIV-1 RT and PIC formation in restricted 
cells but that these complexes are apparently unable to enter the 
nucleus (  Anderson et al., 2006  ;   Wu et al., 2006  ). Therefore, viral 
sequestration within cytoplasmic bodies represents a mechanistic 
explanation for these fi  ndings, as the reverse transcribing genome 
trapped within these structures would likely be unable to interact 
with cellular factors required for entry into the nucleus (  Fig. 1 A  ). 
  We did not observe every cytoplasmic viral complex asso-
ciating with rhTRIM5     cytoplasmic bodies during MG132 treat-
ment (  Fig. 1 C   and   Table I  ). The relatively high intensity of 
fl  uorescent signal associated with large rhTRIM5     cytoplasmic 
bodies after MG132 treatment necessitated very short exposure 
times to obtain unsaturated signal in these images (  Fig. 1 A  ). 
This short exposure time may have been insuffi  cient to detect 
weaker signals associated with small amounts of rhTRIM5    
associating with HIV-1 capsids. 
we synchronously infected rhTRIM5    -HA HeLa cells with this 
FlAsH- p24 
CA    –   and mCherry-Vpr  –  labeled virus in the presence 
of MG132 and BafA or in the absence of drug. When these cells 
were fi  xed 6 h after infection, there was more virus visible in 
cells that had been infected in the presence of MG132 or BafA 
relative to the infection performed in the absence of drug ( Fig. 5 A ), 
which is similar to the pattern observed in the case of wild-type 
virus (  Fig. 4, A and B  ). Association of these viral complexes 
with rhTRIM5     signal was also readily apparent in MG132-
treated cells, whereas there were only background levels of asso-
ciation visible in cells that were infected in the absence of 
drug or in the presence of BafA (  Fig. 5, B and D  ). Therefore, 
we   examined the intensity of the FlAsH capsid signal in viral 
complexes  that were associated with rhTRIM5     signal  and 
compared that intensity to viral complexes observed in the other 
control infections. We did not observe any reduction in the FlAsH 
capsid signal in viral complexes associated with rhTRIM5    
relative to viral complexes observable after the BafA control infec-
tion or the infection performed in the absence of drug (  Fig. 5 D  ). 
This   indicates that if rhTRIM5     does act to induce the loss of 
capsid protein from the viral ribonucleoprotein complex, this 
loss of capsid is a proteasome-sensitive step in rhTRIM5   -
mediated restriction, which is consistent with another recent 
study (  Diaz-Griffero et al., 2007  ). 
  Analyzing the dynamics of rhTRIM5     
and HIV-1 interactions 
  We also used live cell microscopy to monitor the interaction 
  between HIV-1 and rhTRIM5     interaction in real time to gain a 
better understanding of this rapidly occurring dynamic inter-
action. To this end, we infected a HeLa cell line stably express-
ing YFP-rhTRIM5   , which effectively restricts HIV-1 infection 
(  Campbell et al., 2007a  ), with mCherry-Vpr  –  labeled HIV-1 viri-
ons and monitored the interaction between YFP-rhTRIM5     and 
HIV-1 viral complexes. Z stacks of images were acquired every 
10  –  15 s for 10 min or more. These experiments revealed three 
distinct types of interactions between HIV-1 viral complexes 
and YFP-rhTRIM5     protein. In the fi  rst type, viral complexes 
could be seen associating with and traffi  cking with preexisting 
cytoplasmic bodies (  Fig. 6   and Video 1, available at http://www
.jcb.org/cgi/content/full/jcb.200706154/DC1). In this example, 
the YFP-rhTRIM5     body and HIV-1 complex was maintained 
for 6 min while traffi  cking a considerable distance within the 
cell, demonstrating the stability of this association (  Fig. 6  ). 
  In the second type of interaction, HIV-1 viral complexes 
again encountered a preexisting rhTRIM5     cytoplasmic body 
but, this time, dissociated from this interaction apparently 
coated with protein derived from the original preexisting body 
(  Fig. 7 A   and Videos 2 and 3, available at http://www.jcb.org/
cgi/content/full/jcb.200706154/DC1). To confi  rm this hypoth-
esis, we quantifi  ed the total fl  uorescence intensity of the indi-
cated cytoplasmic body over the course of its interaction with 
virus. We observed a measurable loss of fl  uorescent signal in 
the original YFP-rhTRIM5     body coinciding with dissocia-
tion of the viral complex now interacting with a newly formed 
YFP-TRIM5     body (  Fig. 7 B   and Fig. S2 A). This demon-
strates that the new body observed around the indicated viral JCB • VOLUME 180 • NUMBER 3 • 2008  558 
traffi  cking with these bodies over time within cells (  Fig. 6   and 
Video 1). Second, we also observed that interaction between 
rhTRIM5     bodies and HIV-1 could lead to the dynamic transfer 
of rhTRIM5     protein from a preexisting cytoplasmic body onto 
a viral complex in close proximity (  Fig. 7 A   and Videos 2 and 3). 
This is consistent with our recent observation showing that cy-
toplasmic bodies are dynamic structures capable of rapidly sep-
arating and condensing to form smaller and larger cytoplasmic 
bodies, respectively (  Campbell et al., 2007a  ). Third, we also 
observed the rapid association of large amounts of rhTRIM5    
with HIV-1 viral complexes, forming a structure indistinguish-
able from a cytoplasmic body (  Fig. 7 B   and Videos 4 and 5). 
The ability of rhTRIM5     to dynamically reorganize its localiza-
tion upon encountering a cytoplasmic viral complex represents 
a mechanism by which rhTRIM5     protein associates with and 
concentrates around the viral capsid structure during restriction. 
In all cases, the outcome is a viral capsid associated with a discrete 
localized accumulation of rhTRIM5     that meets the defini-
tion of a cytoplasmic body. Collectively, these results reveal that 
diverse types of interactions between rhTRIM5     and HIV-1 
  The observed association of rhTRIM5     and HIV-1 cyto-
plasmic viral complexes had the expected specifi  city. The asso-
ciation of GFP-Vpr  –  labeled viral complexes with rhTRIM5    
was only observed to be above background levels when the HIV 
capsid surface became accessible to the cytoplasmic rhTRIM5    
protein after fusion (  Table I  ). Furthermore, viral cores shown to 
have entered the cytoplasm, as indicated by loss of the S15 
membrane label, preferentially associated with rhTRIM5     ( Figs.  1 
and 3   and   Table I  ). Moreover, we also fi  nd that mutations within 
the B30.2 domain that abrogate restriction (  Sawyer et al., 2005  ) 
also reduce the association between HIV-1 and rhTRIM5    
cytoplasmic bodies to background levels (  Fig. 3, B and C  ), 
demonstrating that the interactions between rhTRIM5     cyto-
plasmic bodies and HIV-1 refl  ect the ability of rhTRIM5     to 
restrict HIV-1 infection. 
  Using live cell microscopy, we observed three types of 
  interactions leading to an association of rhTRIM5     with  cyto-
plasmic HIV-1 during infection, underscoring the dynamic nature 
of these complexes. First, HIV-1 cytoplasmic complexes were 
observed interacting with preexisting cytoplasmic bodies and 
  Figure 6.       Stable interaction between rhTRIM5     cytoplasmic bodies and HIV-1 virions.   HeLa cells expressing YFP-rhTRIM5     (green) were infected with mCherry-
Vpr  –  labeled HIV-1 virions (red). Images were acquired every 15 s for 10 min. Arrows indicate one YFP-rhTRIM5     cytoplasmic body associating and trafﬁ  cking 
with one mCherry-Vpr  –  labeled virus over time. The bottom right panel shows the path traveled by the YFP-rhTRIM5      –   and mCherry-Vpr  –  labeled virion throughout 
the experiment. The provided image is one z section from a deconvolved z-stack image showing the z section in which the interaction is currently trafﬁ  cking.     559  ASSOCIATION OF HIV-1 WITH RHESUS TRIM5       •   CAMPBELL ET AL.
restrict infection. Our observation that rhTRIM5     can induce the 
de novo nucleation of rhTRIM5     protein around a cytoplasmic 
viral complex further supports a mechanism in which rhTRIM5    
could restrict HIV-1 infection by multimerizing into higher order 
structures to increase the localized concentration of restriction 
factor around a cytoplasmic viral core. Cytoplasmic bodies may 
therefore represent the ability of rhTRIM5     to form localized 
concentrations of proteins in specifi  c locations, such as around 
viral cores, as this ability to multimerize into higher order struc-
tures around a core would increase the avidity of the interaction 
between rhTRIM5     and the viral complex. 
  Fate of capsid during restriction 
  Our assay for the presence of p24 
CA   within the intermediate of 
restriction observed with proteasome inhibition reveals that 
there are similar amounts of p24 
CA   present in the complexes of 
GFP-Vpr  –  labeled HIV complexes as is found in intact viral 
cores (  Fig. 5  ). At fi  rst glance, this observation would seem to be 
in confl  ict with reports that rhTRIM5     restricts HIV infection 
by mediating premature disassociation of the HIV conical capsid 
cytoplasmic complexes can lead to the formation of a complex of 
rhTRIM5     protein bound to an HIV-1 capsid in the context of a 
cell line expressing YFP-rhTRIM5     (  Fig. 7 B   and Videos 4 and 5). 
In a situation in which rhTRIM5     expression is lower and cyto-
plasmic bodies are not readily apparent, the de novo formation 
of rhTRIM5     on the HIV core would no doubt predominate. 
 Moreover, in vitro studies demonstrate that TRIM5 proteins 
associate with incoming viral capsids (  Sebastian and Luban, 
2005  ;   Stremlau et al., 2006  ). Importantly, these studies show that 
TRIM5     does not recognize or bind free capsid protein but rather 
only binds capsid protein in the context of the larger viral core 
(  Sebastian and Luban, 2005  ;   Stremlau et al., 2006  ). TRIM pro-
teins are also reported to form trimers and higher order oligomers 
(  Reymond et al., 2001; Mische et al., 2005  ). This ability to oligo-
merize, as measured by biochemical cross-linking, is reported to 
be critical for the ability of rhTRIM5     to recognize purifi  ed cap-
sid cores and restrict retroviral infection ( Javanbakht et al., 2006 ). 
These studies cumulatively suggest that the ability of TRIM5     to 
concentrate around a viral core is a requisite step in retroviral 
restriction, as TRIM mutants that cannot oligomerize cannot 
  Figure 7.       Dynamic interactions between rhTRIM5     cytoplasmic bodies and HIV-1 virions.   (A and C) HeLa cells expressing YFP-rhTRIM5     (green) were 
infected with mCherry-Vpr  –  labeled HIV-1 virions (red). Images were acquired every 10 s for 15 min. Virus could induce the formation of new cytoplasmic 
bodies by becoming coated with YFP-rhTRIM5     protein derived from a preexisting cytoplasmic body (A) or by the de novo formation of a cytoplasmic body 
around a virion (C). (B and D) Quantifying these interactions conﬁ  rms that the YFP-rhTRIM5     signal (vTRIM) becoming associated with an mCherry-Vpr  –  labeled 
virion (virus 1) in C derives from a preexisting rhTRIM5     body (TRIMbody) at the time point indicated by the arrows. The provided images were derived 
from a volume compression of a z stack of 10 images taken at a 0.5-    m step size at each time point.     JCB • VOLUME 180 • NUMBER 3 • 2008  560 
  Materials and methods 
  Cells and pharmaceuticals 
  293T and HeLa cells were obtained from the American Type Culture 
  Collection. rhTRIM5    -HA  –  expressing HeLa cells were gifts from J. Sodroski 
(Harvard Medical School, Boston, MA). CRFK cells stably expressing 
rhTRIM5    -HA or rhTRIM5        patch-HA were provided by M. Emerman 
(Fred Hutchinson Cancer Center, Seattle, WA). Cells were cultured as pre-
viously described (  Wu et al., 2006  ). BafA1 (Sigma-Aldrich) was prepared 
in DMSO and diluted to a ﬁ  nal concentration of 20 nm in DME. MG132 
(Sigma-Aldrich) was prepared in ethanol and diluted to a ﬁ  nal concentra-
tion of 1     g/ml. 
  Virus generation 
  The tetracysteine motif was introduced into the cyclophilin-binding loop of 
capsid (H87C/A88C/I91C/A92C) of the proviral strain R7    env GFP by 
segment overlap PCR and using BssHII  –  SpeI restriction enzyme sites for 
cloning to create R7    env GFP  FC   (HIV  FC   in the text). 
  To produce virus, 10-cm plates of 293T virus-producing cells were 
transfected with the appropriate plasmids using polyethylenimine (mol wt 
of 25,000 kD; Polysciences). GFP-Vpr  –   or mCherry-Vpr  –  labeled virus and 
GFP-Vpr and S15-mCherry dually labeled virus were prepared as previ-
ously described (  McDonald et al., 2002; Campbell et al., 2007b  ). GFP-
Vpr  –  labeled NL43 virions were produced by cotransfecting 17.5   μ  g NL43 
proviral plasmid DNA with 2.5     g GFP-Vpr. HIV  FC   virus was generated by 
cotransfecting 12   μ  g HIV  FC  , 8   μ  g VSV-G, and 1.5   μ  g mCherry-Vpr, whereas 
mixed HIV  FC   (HIV  FCM  ) was generated by cotransfecting 6   μ  g R7    env GFP, 
6   μ  g pHIV  FC  , 8   μ  g VSV-G, and 1.5   μ  g mCherry-Vpr. Virus was harvested 
38 h after transfection and ﬁ  ltered through a 0.22-    m ﬁ  lter. Virus concen-
tration was determined by p24 
CA   ELISA (PerkinElmer). 
  FlAsH labeling solution was prepared by incubating 0.2     M FlAsH 
reagent (Invitrogen) with 1     l DMSO for 10 min at room temperature. 200     l 
HBSS supplemented with 1 mg/ml glucose was then added to the labeling 
solution and incubated for 15 min at room temperature. Labeling solution 
was then added to 2 ml of virus and incubated for 2 h at 37  °  C. Unbound 
FlAsH reagent was removed by ultracentrifugation of the virus through a 
30% sucrose cushion. Virus was resuspended in DME and assayed for p24 
concentration by ELISA (PerkinElmer). 
  Infections 
  Synchronized infections were performed as previously described (  O  ’  Doherty 
et al., 2000; Campbell et al., 2007b  ). Cells were spinoculated with virus 
at 17  °  C for 2 h at 1,200   g  . Unbound virus was removed and replaced with 
fresh 37  °  C media to initiate infection. Cells were ﬁ  xed at the indicated 
times after the initiation of infection. Unsynchronized infections were per-
formed at 37  °  C in the constant presence of virus. Glass coverslips were 
ﬁ  xed with 3.7% formaldehyde (Polysciences) in 0.1 M Pipes buffer, pH 6.8. 
Coverslips were stained with mouse or rabbit     -HA antibody (Sigma-Aldrich), 
    -p24 mAb AG3.0 (National Institutes of Health AIDS Research and 
Reference Reagent Program),     -ubiquitin monoclonal antibody P4D1 (Santa 
Cruz Biotechnology, Inc.), or     -20S proteasome     -subunit polyclonal anti-
body (EMD) followed by ﬂ  uorescently labeled secondary antibodies (Jackson 
ImmunoResearch Laboratories). 
  Imaging 
  Images were collected on a digital camera (CoolSNAP HQ; Photometrics) 
using a 100  ×   NA 1.4 objective lens and were deconvolved with a micro-
scope (DeltaVision) and DeltaVision software (Applied Precision). 
  Virus infectivity was analyzed by adding equal amounts of virus 
normalized by p24 ELISA (PerkinElmer) onto control HeLa cells or HeLa 
cells stably expressing HA-tagged rhTrim5    . GFP expression was mea-
sured 48 h later using a ﬂ  ow cytometer (FACSCalibur; Becton Dickinson) 
analyzing 5,000 events per infection. 
  Live cell microscopy 
  Cells stably expressing YFP-rhTRIM5     (  Campbell et al., 2007a  ) were 
plated in delta DPG dishes (Thermo Fisher Scientiﬁ  c) in DME/F-12 50/50 
(Mediatech, Inc.) containing 20% FBS, 100 U/ml penicillin, 100   μ  g/ml 
streptomycin, 292   μ  g/ml    L-  glutamine, and 10   μ  g/ml ciproﬂ  oxacin  the 
night before imaging. Virus was allowed to bind the cells for 1 h at 17  °  C. 
Virus was then removed and replaced with fresh 37  °  C DME/F-12 50/50 
media and incubated for 5 min at 37  °  C before imaging. Cells were im-
aged at 37  °  C on a DeltaVision microscope, and images were captured in 
a z series on an electron multiplied charge coupled device digital camera 
(Cascade 2; Photometrics) and deconvolved using SoftWoRx deconvolu-
tion software (Applied Precision). In the presented images, the threshold 
as proposed by the Sodroski laboratory (  Perron et al., 2004  ; 
  Stremlau et al., 2006  ). However, a recent paper from that labo-
ratory showing that the facilitated uncoating mediated by 
rhTRIM5    is proteasome dependent ( Diaz-Griffero et al., 2007 ) 
is consistent with the two-step model of restriction that we have 
proposed previously (  Anderson et al., 2006  ) and is consistent with 
the results presented here, which suggest that a proteasome-
independent structure consisting of an HIV capsid coated with 
large amounts of rhTRIM5     is a key intermediate in the mecha-
nism of restriction of HIV infection by this protein. 
  We also observed that rhTRIM5     cytoplasmic bodies con-
taining sequestered HIV-1 viral complexes contain ubiquitin 
(  Fig. 4 C  ). This suggests that in the absence of proteasome in-
hibitor, proteasome activity would play a role in the disruption of 
cytoplasmic viral complexes. We have shown that rhTRIM5     is 
rapidly turned over (  Wu et al., 2006  ), and others have shown that 
this rapid turnover can be infl  uenced by polyubiquitination and 
proteasome-mediated degradation of rhTRIM5     ( Diaz-Griffero 
et al., 2006  ). These data collectively suggest that in the absence 
of drug, rhTRIM5     binds HIV-1 capsid determinants in the 
cytoplasm and mediates restriction by a mechanism that involves 
proteasome-dependent degradation of the rhTRIM5     protein. 
  The precise mechanism by which proteasome activity me-
diates this second step in the restriction process requires further 
investigation. Our data have failed to demonstrate a concentra-
tion of ubiquitin on viral complexes sequestered within cyto-
plasmic bodies, although the bodies sequestering these viral 
complexes do contain ubiquitin (  Fig. 4  ). With no evidence show-
ing that the viral capsid is polyubiquitylated, perhaps protea-
somes target polyubiquitylated rhTRIM5     during restriction 
and not the viral capsid protein. rhTRIM5     insertion into the 
capsid lattice of incoming viral cores (  Mische et al., 2005  ) and 
the subsequent dislocation of rhTRIM5     during its degradation 
by the proteasome could induce signifi  cant strain on the capsid 
structure, perturbing the integrity of the viral capsid lattice and 
causing the capsid lattice to fall apart in the absence of direct 
capsid degradation. Moreover, this model would also explain 
the loss of HIV viral complexes observed during restriction via 
imaging here, where dissociation of the viral capsid lattice into 
individual capsid proteins would allow diffusion of the concen-
trated GFP-Vpr signal used to identify viral complexes. There-
fore, a model invoking the proteasome-mediated turnover of 
TRIM5 proteins inserted into incoming retroviral capsid lattices 
and subsequent dissociation of the capsid lattice could reconcile 
our observations that TRIM5 restriction involves proteasomes 
(  Anderson et al., 2006  ;   Wu et al., 2006  ) with the Sodroski labo-
ratory fi  ndings that restriction occurs without any apparent deg-
radation of the viral capsid protein (  Stremlau et al., 2006  ). 
  The data presented here collectively reveal the importance 
of rhTRIM5     cytoplasmic bodies for rhTRIM5     restriction of 
HIV-1 and further inspire a novel view of the restriction process 
in which the ability of rhTRIM5     protein to concentrate around 
a cytoplasmic viral core likely plays an important role in the 
mechanism to restrict invading retroviruses. Future work is re-
quired to better understand how proteasome activity mediates 
the destruction of the restriction intermediate observed when 
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ﬂ  uorescent intensity was set to allow the visualization of all virions above 
background. Because virion labeling is heterogeneous, this led to post-
acquisition saturation of extremely ﬂ  uorescent virions, giving them the 
appearance of being larger. This is only a result of the threshold required 
to view poorly labeled virions, and these virions can be observed to be 
punctate virions of appropriate size when a threshold more appropriate for 
an intensely labeled virion is used. 
  Data analysis 
  Deconvolved data were corrected for channel-speciﬁ  c phase shifts in the z axis 
and analyzed manually using Imaris software (Bitplane). Individual GFP-Vpr  –
  positive virions were assessed for the presence of S15-mCherry stain and local-
ization within an area of cytoplasmic rhTRIM5     concentration. For virion 
quantiﬁ  cation, any punctate signal in the GFP channel above background was 
counted as a virion. Any signal above background in the rhTRIM5     channel 
was counted as rhTRIM5     association. The data quantiﬁ  cations shown re-
ﬂ  ect the mean results from two (  Fig. 1 B   only) or three independent experi-
ments. Error bars represent the SEM of the individual calculated means. 
In   Fig. 4 (A and B)  , the number of virions present in the 1-h BafA slide was 
set to 100% to normalize differences in viral input between experiments. 
  Live cell analysis was performed using the data inspector function 
on SoftWoRx software. The total intensity of a 6   ×   6  –  pixel region of interest 
was measured, and the ﬁ  nal total intensity at each time point was calcu-
lated by subtracting the mean total intensity of three similar regions without 
visible ﬂ  uorescent signal. 
  Online supplemental material 
  Fig. S1 shows validation of the HIV  FCM   virus, demonstrating that the virus is 
labeled by FlAsH reagent, which was infectious and appropriately restricted 
by rhTRIM5    . Fig. S2 shows additional ﬂ  uorescence quantiﬁ  cation of the 
interactions observed in Videos 3 and 5 as performed in   Fig. 7 (C and D)  . 
Video 1 shows an mCherry-Vpr  –  labeled HIV-1 virion trafﬁ  cking with a pre-
existing YFP-rhTRIM5     cytoplasmic body over the course of 6 min. Videos 2 
and 3 show the association of an mCherry-Vpr  –  labeled virion and YFP-
rhTRIM5     cytoplasmic body terminating with an amount of YFP-rhTRIM5     
protein remaining associated with the virion. Videos 4 and 5 show the de novo 
formation of a YFP-rhTRIM5     cytoplasmic body around an mCherry-Vpr  –
  labeled virion. Online supplemental material is available at http://www
.jcb.org/cgi/content/full/jcb.200706154/DC1. 
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